Apparatus and method for for analyzing chronic inflammatory disease based on genome-wide association analysis
The method and device for whole-genome association analysis identify significant single nucleotide polymorphisms associated with increasing hsCRP gradients, addressing the limitations of single measurements by providing diagnostic information for chronic inflammation and therapeutic targets, facilitating proactive intervention in chronic diseases.
Patent Information
- Application Number
- KR1020230006207
- Authority / Receiving Office
- KR · KR
- Patent Type
- Patents
- Current Assignee / Owner
- Priority Date
- 2022-01-17
- Filing Date
- 2023-01-16
- Publication Date
- 2026-11-11
- Estimated Expiration
- 2043-01-16
AI Technical Summary
Conventional genome-wide association studies on high-sensitivity C-reactive protein (hsCRP) primarily use single measurements, failing to accurately represent its role as an inflammation marker and neglecting the variability that changes over time, which is crucial for predicting chronic inflammatory diseases.
A method and device for analyzing chronic inflammatory diseases through whole-genome association analysis, identifying significant single nucleotide polymorphisms associated with increasing hsCRP gradients in high-risk groups using a linear regression model and genomic data from subjects with hsCRP levels above a threshold and a rising trend, generating diagnostic information for chronic inflammation.
This approach identifies biomarkers that reflect the increasing trend of hsCRP, providing insights into immune inflammation and potential therapeutic targets, enabling proactive intervention in chronic inflammatory diseases like chronic kidney disease, and supporting personalized medicine.
Smart Images

Figure 112023005775744-PAT00002_ABST
Abstract
Description
Technology Field
[0001] The present invention relates to an apparatus and method for analyzing chronic inflammatory diseases based on whole-genome association analysis. For example, the present invention relates to an indicator, composition, kit, and method for predicting chronic inflammation in Koreans using gene single nucleotide polymorphisms associated with an increase in the hsCRP gradient in high-sensitivity C-reactive protein (hsCRP) high-risk groups via whole-genome association analysis. Background Technology
[0002] Chronic inflammatory processes have been shown to play a significant role in various chronic diseases, such as cardiovascular, respiratory, renal, and neurological disorders, in addition to traditionally recognized inflammatory diseases. High-sensitivity C-reactive protein (hsCRP), one of the most common biomarkers of inflammation, is used as a systemic inflammation marker in clinical settings and is considered to be associated with the severity of the inflammatory response. Specifically, hsCRP is an acute-phase reactant produced in the liver and is secreted into the bloodstream in response to the presence of pro-inflammatory cytokines; elevated inflammatory markers can be considered a significant risk factor for chronic kidney disease. Previous studies have demonstrated that elevated serum hsCRP at a single time point is an important predictor of cardiovascular health in both the general population and dialysis patients.
[0003] However, since hsCRP levels are generally not fixed and conventional studies on the relationship between hsCRP and chronic kidney disease have primarily been based on hsCRP measurements at a single time point, there is a problem in that a single measurement of hsCRP may not accurately represent its role as an inflammation marker.
[0004] In fact, in hemodialysis patients, serum hsCRP levels have shown a tendency to increase annually during the follow-up period, and it has also been reported that the steady increase in hsCRP levels over time is associated with mortality from all-cause and cardiovascular diseases.
[0005] The heritability of CRP is estimated to be 25–40%, which suggests that genetic variation is one of the major determinants of CRP levels and implies the value of attempting genome-wide association studies on hsCRP. In a meta-analysis combining results from 15 European studies to derive genetic variation associated with hsCRP, genetic variation related to CRP levels based on genome-wide association studies was reported. Although there is a meta-analysis of genome-wide association studies (GWAS) results related to hsCRP in Asian populations, genome-wide association studies on hsCRP to date have primarily used a single measure of hsCRP and have not essentially accounted for characteristics and variability that change over time.
[0006] Therefore, single polymorphisms derived from genome-wide association analysis of the hsCRP gradient based on subjects with hsCRP levels of 3 mg / L or higher—which serve as the clinical criterion for hsCRP as an inflammatory marker—and who are on an increasing trend (continuous elevation) can be considered to have clinical significance, as they are more likely to reflect biological changes than a single measurement. Nevertheless, the simple identification of genetic variants alone may not be sufficient to understand the increase in the hsCRP gradient in the high-risk hsCRP group (3 mg / L).
[0007] A single variant or a single gene may possess pleiotropic characteristics, which are generally defined as genetic variants that truly affect multiple phenotypes and are one of the underlying causes of observed cross-phenotypic linkage.
[0008] Cross-phenotypic association can occur in the context of biological pleiotropy, where single nucleotide polymorphisms or genes affect multiple phenotypes.
[0009] Cross-phenotype association refers to potential pleiotropy where a variant is associated with multiple traits regardless of the underlying cause, and while genome-wide association analysis is performed to identify single nucleotide polymorphisms associated with a single phenotype, the integration of multiple genome-wide association analysis results may be necessary when estimating the effects of cross-phenotypes.
[0010] Furthermore, identifying genetic variants across multiple phenotypes not only enhances statistical capabilities but can also provide a comprehensive understanding of the underlying shared biological pathways and mechanisms common to various diseases or phenotypes; additionally, the discovery of gene loci associated with multiple diseases can support general interventions. Therefore, there is a need to develop biomarkers that can serve as candidates for drug treatments or to predict the onset and prognosis of related diseases by identifying genetic variants (single nucleotide polymorphisms) associated with the increase in hsCRP gradients in high-risk groups within the general Korean population and exploring related cross-phenotypes. The problem to be solved
[0011] The present invention aims to solve the problems of the aforementioned conventional technology by providing a method for identifying biomarkers related to increased hsCRP gradients and chronic inflammation cross-phenotypes based on whole-genome association analysis, which generates diagnostic information linked to inflammation in subjects by utilizing gene single nucleotide polymorphisms associated with increased hsCRP gradients in high-sensitivity C-reactive protein (hsCRP) high-risk groups through whole-genome association analysis.
[0012] However, the technical problems that the embodiments of the present invention aim to solve are not limited to the technical problems described above, and other technical problems may exist. means of solving the problem
[0013] As a technical means for achieving the above-mentioned technical task, a method for analyzing chronic inflammatory diseases based on whole-genome association analysis according to one embodiment of the present invention may include: a step of collecting genomic information data of a plurality of subjects; a step of selecting genomic information data that satisfies a preset hsCRP level condition based on hsCRP (high-sensitivity C-reactive protein) level information of each of the plurality of subjects; a step of performing whole-genome association analysis based on a linear regression model linked to an hsCRP gradient using the selected genomic information data; and a step of deriving analysis information on single nucleotide polymorphisms that are significantly associated with a phenotype linked to a target disease based on the results of the association analysis.
[0014] In addition, the above target disease may include chronic inflammatory diseases.
[0015] In addition, the screening step may select the genomic information data of a subject among the plurality of subjects in which the hsCRP level is above a preset threshold value during the follow-up period and the change in the hsCRP level is above a preset threshold slope.
[0016] In addition, the step of deriving the analysis information can determine single nucleotide polymorphisms among those derived by the association analysis that are considered to have significant genomic association because their P-value is below a preset threshold.
[0017] In addition, the above single base polymorphism may include rs143984685.
[0018] In addition, a method for analyzing chronic inflammatory diseases based on whole-genome association analysis according to one embodiment of the present invention may include the step of generating diagnostic information for the target disease of a subject using the analysis information.
[0019] Meanwhile, a chronic inflammatory disease analysis device based on whole-genome association analysis according to one embodiment of the present invention may include a collection unit that collects genomic information data of a plurality of subjects and selects genomic information data that satisfies a preset hsCRP level condition based on hsCRP (high-sensitivity C-reactive protein) level information of each of the plurality of subjects, and a statistical analysis unit that performs whole-genome association analysis based on a linear regression model linked to an hsCRP gradient using the selected genomic information data and derives analysis information on single nucleotide polymorphisms that are significantly associated with a phenotype linked to a target disease based on the results of the association analysis.
[0020] In addition, a chronic inflammatory disease analysis device based on whole-genome association analysis according to one embodiment of the present invention may include a diagnostic information generation unit that generates diagnostic information regarding the target disease of a subject using the analysis information.
[0021] Meanwhile, in relation to a composition for detecting a single nucleotide polymorphism (SNP) marker to predict the occurrence and exacerbation of a chronic inflammatory disease according to one embodiment of the present invention, the single nucleotide polymorphism (SNP) marker may be rs143984685.
[0022] Meanwhile, regarding a kit for diagnosing the prediction of the occurrence and exacerbation of chronic inflammatory diseases using a single nucleotide polymorphism (SNP) marker according to one embodiment of the present invention, the single nucleotide polymorphism (SNP) marker may be rs143984685.
[0023] The means for solving the problem described above are merely exemplary and should not be interpreted as intended to limit the present invention. In addition to the exemplary embodiments described above, additional embodiments may exist in the drawings and the detailed description of the invention. Effects of the invention
[0024] According to the solution to the problem described above, a method for identifying biomarkers related to an increase in hsCRP gradient and chronic inflammation cross-phenotype based on whole-genome association analysis can be provided, which generates diagnostic information associated with inflammation in subjects by utilizing gene single nucleotide polymorphisms associated with an increase in hsCRP gradient in high-sensitivity C-reactive protein (hsCRP) high-risk groups through whole-genome association analysis.
[0025] According to the aforementioned means for solving the problem of the present invention, significant biomarkers for the slope of hsCRP can be discovered based on subjects in whom the hsCRP level, which is a clinical criterion for hsCRP inflammation levels, is 3 mg / L or higher, and at the same time, the hsCRP is on an increasing trend (continuously rising).
[0026] According to the solution to the problem of the present invention described above, unlike conventional genetic variations associated with hsCRP that were identified only as specific genetic markers of hsCRP because they were associated with a single measurement of hsCRP, genetic variations associated with the increasing trend of hsCRP in high-risk groups can be identified as having cross-expression associations with various chronic inflammation indicators.
[0027] According to the aforementioned means for solving the problem of the present invention, it may be helpful to clarify the role of immune inflammation and conduct more direct examinations related to rapidly increasing inflammation.
[0028] According to the solution to the problem described above, by estimating the influence of genetic variations within circulating biological metabolic mechanisms, insights into the prevention and intervention of inflammation-related diseases can be provided through continuous monitoring of subjects with an increasing trend in hsCRP levels within the high-risk hsCRP group.
[0029] According to the aforementioned means for solving the problem of the present invention, by estimating the influence of genetic variations on metabolites within circulating biological metabolic mechanisms, insights into prevention and intervention can be provided through continuous monitoring of hypertensive patients at high risk of progression of chronic kidney disease.
[0030] According to the solution to the problem of the present invention described above, the biomarker has sufficient clinical significance as it demonstrates potential as a comprehensive indicator of chronic inflammation and can provide opportunities for the development of new drugs based on drug targets for the HELZ gene in the future.
[0031] However, the effects obtainable from this invention are not limited to those described above, and other effects may exist. Brief explanation of the drawing
[0032] FIG. 1 is a schematic diagram of a device for analyzing chronic inflammatory diseases based on whole-genome association analysis according to one embodiment of the present invention. Figure 2 shows the Manhattan plot and Q-Q plot of the whole-genome association analysis of the Discovery dataset for the increase in hsCRP slope. Figure 3 is a diagram showing the genomic characteristics of rs143984685 in 17q24.2. Figure 4 is a diagram showing verified single nucleotide polymorphisms associated with an increase in hsCRP gradient based on whole-genome association analysis. Figure 5 is a graph showing the fine-mapping results of rs143984685 in the HELZ gene of chromosome 17q24.2. FIG. 6 is a flowchart of the operation of a method for analyzing chronic inflammatory diseases based on whole-genome association analysis according to one embodiment of the present invention. Specific details for implementing the invention
[0033] Embodiments of the present invention are described below with reference to the attached drawings to enable those skilled in the art to easily implement the invention. However, the present invention may be embodied in various different forms and is not limited to the embodiments described herein. Furthermore, in order to clearly explain the present invention in the drawings, parts unrelated to the explanation have been omitted, and similar parts throughout the specification are denoted by similar reference numerals.
[0034] Throughout this specification, when a part is described as being "connected" to another part, this includes not only cases where they are "directly connected," but also cases where they are "electrically connected" or "indirectly connected" with other elements interposed between them.
[0035] Throughout the entire specification, when a component is described as being located "on," "on top," "on top," "under," "on bottom," or "on bottom" of another component, this includes not only cases where the component is in contact with the other component but also cases where another component exists between the two components.
[0036] Throughout this specification, when a part is described as "comprising" a certain component, this means that, unless specifically stated otherwise, it does not exclude other components but may include additional components.
[0037] The present invention relates to an apparatus and method for analyzing chronic inflammatory diseases based on whole-genome association analysis. For example, the present invention relates to an indicator, composition, kit, and method for predicting chronic inflammation in Koreans using gene single nucleotide polymorphisms associated with an increase in the hsCRP gradient in high-sensitivity C-reactive protein (hsCRP) high-risk groups via whole-genome association analysis.
[0038] FIG. 1 is a schematic diagram of a device for analyzing chronic inflammatory diseases based on whole-genome association analysis according to one embodiment of the present invention.
[0039] Referring to FIG. 1, a whole-genome association-based chronic inflammatory disease analysis device (100) (hereinafter referred to as the 'analysis device (100)') according to one embodiment of the present invention may include a collection unit (110), a statistical analysis unit (120), and a diagnostic information generation unit (130).
[0040] The collection unit (110) can collect genomic information data of multiple subjects.
[0041] Additionally, the collection unit (110) can select genomic information data that satisfies preset hsCRP level conditions based on hsCRP (high-sensitivity C-reactive protein) level information of each of the multiple subjects.
[0042] Specifically, the collection unit (110) can perform data preprocessing to select genomic information data of subjects among a plurality of subjects in which the hsCRP level during the follow-up observation period corresponds to a preset threshold value (e.g., 3 mg / L, etc.) or higher, and the change in the hsCRP level corresponds to a preset threshold slope (e.g., 0, etc.) or higher.
[0043] The statistical analysis unit (120) can perform whole-genome association analysis based on a linear regression model linked to the hsCRP gradient using selected genomic information data, as described in detail below.
[0044] Additionally, the statistical analysis unit (120) can derive analysis information regarding single nucleotide polymorphisms that are significantly associated with a phenotype associated with a target disease based on the results of the association analysis. In the description of the embodiments of the present invention, a single nucleotide polymorphism that is significantly associated with a phenotype associated with a target disease, which is a chronic inflammatory disease, may include rs143984685.
[0045] The diagnostic information generation unit (130) can generate diagnostic information for the subject's target disease (in other words, chronic inflammatory disease) using the analysis information.
[0046] Below, the specific functions and operations of the analysis device (100) will be described with reference to FIGS. 2 to 5.
[0047] FIGS. 2 to 5 are drawings illustrating a method for identifying biomarkers related to hsCRP gradient increase and chronic inflammation cross-phenotype based on whole-genome association analysis according to one embodiment of the present invention.
[0048] According to one embodiment of the present invention, the analysis device (100) can collect the hsCRP (high-sensitivity C-reactive protein) levels of a subject during a follow-up observation period.
[0049] Additionally, the analysis device (100) can generate diagnostic information associated with the degree of inflammation of the subject based on the collected hsCRP levels and the time series change of the hsCRP levels.
[0050] The following describes in detail the hsCRP level analysis and biomarker identification process.
[0051] Single Nucleotide Polymorphism (SNP) refers to the phenomenon where traits are expressed differently between individuals due to genetic variations that show differences in the nucleotide sequences present in DNA between individuals. Among the causes of polymorphism, a single nucleotide polymorphism (SNP) is defined as the expression of different traits caused by variations in a single pair of nucleotide sequences that occur frequently in a population (usually with a frequency of 1% or more).
[0052] Genome-wide association study (GWAS) is an analytical method that identifies genetic variations associated with related phenotypes at all genomic locations.
[0053] MAF (Minor allele frequency) refers to the proportion of chromosomes bearing a specific allele out of the total number of alleles. It refers to the second most frequent variant in a given population and primarily represents the proportion of chromosomes containing effector alleles.
[0054] An allele refers to a gene that forms a pair of homologous chromosomes and has different traits, and means the DNA sequence of the allele.
[0055] The P-value represents the probability that the test statistic is equal to or more extreme than the observed statistic, assuming the null hypothesis is true.
[0056] In addition, the "rs number" or "NCBI refSNP ID" is a unique number of SNPs registered in the SNP reference database of the National Center for Biotechnology Information (NCBI), and information about the SNP can be verified by accessing the database through this unique number. Therefore, once the rs number is specified in this invention, a person skilled in the art can easily verify information about the SNP, such as the chromosomal location where the SNP exists, genetic loci, and polymorphic sequences containing the SNP.
[0057] Fine-mapping provides evidence that genomic regions are associated with phenotypes and assumes the existence of at least one causative variant to determine genetic variation, thereby enabling the identification of a credible set of potential causative variants for which probabilistic selection can be prioritized.
[0058] The "hsCRP slope" refers to the annual change in hsCRP and can be identified, for example, by measuring hsCRP values over time and plotting them on a graph with the vertical axis representing hsCRP value and the horizontal axis representing time (period). A steeper hsCRP slope indicates a more severe level of inflammation in the human body. In this regard, our institution may define subjects with an hsCRP value of 3 mg / L at baseline and follow-up as the "hsCRP high-risk group."
[0059] Meanwhile, in the description of the embodiments of the present invention, cross-phenotype refers to a potential pleiotropy in which a variation is associated with various traits regardless of the underlying cause.
[0060] Hereinafter, with reference to FIGS. 2 to 5, an experimental example associated with a method for identifying biomarkers related to hsCRP gradient increase and chronic inflammation cross-phenotype based on whole-genome association analysis according to one embodiment of the present invention will be described.
[0061] Specifically, Figure 2 shows the Manhattan plot and Q-Q plot of the whole-genome association analysis of the Discovery dataset for the increase in hsCRP slope, and Figure 3 shows the genomic characteristics of rs143984685 in 17q24.2. Specifically, Figure 3 (A) is a regional plot of the region surrounding rs143984685 in 17q24.2. The red dot indicates the most strongly linked read single nucleotide polymorphism rs143984685 (purple diamond). Additionally, Figure 3 (B) shows the fine-mapping results for rs143984685, and a posterior probability of inclusion (PIP) plot of the fine-mapping around rs143984685 at + / - 100 kb intervals. In the plot, the single nucleotide polymorphisms around the blue circles are a reliable set with potential causal relationships.
[0062] In addition, Figure 4 is a graph showing verified single nucleotide polymorphisms associated with an increase in hsCRP gradient based on whole-genome association analysis, and Figure 5 is a graph showing the fine-mapping results of rs143984685 in the HELZ gene of chromosome 17q24.2.
[0063] a) Research subjects
[0064] 1) Discovery / validation genotyping dataset
[0065] This study was conducted as part of the project “Utilization of Genomic Information and Linkage of Public Data in Korean Genomic Epidemiology Data” under the Post-Genome Multi-Ministerial Genomics Project, which began in July 2020. It involved obtaining epidemiological information from the Korean Chip-based community-based, urban-based, and rural-based cohorts, as well as omics big data (genotype, epigenome, metabolite), from the Korea National Institute of Health (NIH) of the Korea Genome Epidemiology Study (KoGES), which is one of the largest cohort data sources representing the general Korean population. To obtain this data, a research plan and an application for exemption from review were submitted to the Institutional Review Board (IRB) of Seoul National University Hospital, and a notification of exemption was ultimately received. Based on the notification of exemption and the research plan, epidemiological information and omics big data based on the Korean Chip genomic information of a total of 72,298 individuals were obtained from the Human Resource Distribution Desk of the Korea Disease Control and Prevention Agency. The Korean Chip Consortium genomic data was developed as a biobank array optimized for Korean genomic information to address the shortcomings of existing commercial single polymorphism chips, which are designed primarily for Western populations and thus lack genomic representativeness for Asians. This data was actively utilized in this study because it ensures the representativeness of the Korean genome by including Korean genetic mutation markers. Among these, only the urban-based and community-based cohorts were investigated for hsCRP during baseline and follow-up observations. Therefore, the urban-based cohort, which has a large number of subjects within the Korean Chip Consortium, was utilized as the discovery genotyping dataset, while the community-based cohort was used as the validation dataset. Among subjects whose hsCRP levels were 3 mg / L or higher during the follow-up period (the urban cohort distributed data up to the first follow-up period in addition to the base, while the community-based cohort considered up to the third follow-up period to reduce heterogeneity in the follow-up period compared to the urban cohort), only those whose change in hsCRP (slope) was greater than 0 were included in the study, and 308 subjects from the urban-based cohort and 18 subjects from the community-based cohort were selected as the final study subjects.
[0066] b) Genotype Analysis and Quality Control
[0067] 1) Discovery / validation genotyping dataset: Korean Chip Consortium
[0068] The fabrication of the Korean Chip and the production of genomic information using the Korean Chip were carried out according to the following protocol, the detailed protocol of which is available from the Korean Chip Consortium. To maximize genomic representativeness for the Korean genome, a pilot chip was fabricated by selecting highly accurate genetic variants based on DNA sequences extracted from 2,576 Koreans, and the final content was selected based on the results of analyzing the genomic information of 384 subjects. Genomic Coverage of over 95% (MAF) Single nucleotide polymorphisms of 5%) and over 73% (MAF 1–5%) were included, including functional variations, pharmacogenomic variations, eQTL variations affecting gene expression, and HLA region variations found in the Korean population. Ultimately, approximately 8,000,000 single nucleotide polymorphisms specific to the Korean population were included in the analysis.
[0069] c) Statistical analysis
[0070] 1) GWAS Analysis
[0071] The change in hsCRP (slope) was calculated by dividing the difference between the first and last measurement times by the follow-up years. To explore genetic variations associated with the hsCRP slope in subjects who showed hsCRP levels of 3 mg / L or higher during the follow-up period and had an hsCRP change (slope) > 0, genome-wide association analysis of the hsCRP slope was performed using linear regression analysis. This was based on PLINK (version 2.0) and assumed an additive genetic model based on the city-based cohort of the Korean Chip Consortium. Among the derived single nucleotide polymorphisms, those with a P-value less than 1E-07 were considered to have a significant genomic association. To verify the significant association of single nucleotide polymorphisms found in the Korean Chip Consortium, the community-based cohort of the Korean Chip Consortium was used; as there were no overlapping subjects, it can be considered an independent dataset. In the validation procedure, single nucleotide polymorphisms with a P-value of less than 0.05 were considered validated. Manhattan plots and QQ (Quantile-Quantile) plots were plotted using R software version 4.1.0 (R Development Core Team; R Foundation for Statistical Computing, Vienna, Austria). Linkage disequilibrium (LD) clumping for single nucleotide polymorphisms was performed based on a 10,000kb window and R² < 0.001, and annotations for all single nucleotide polymorphisms were performed using the ANNOVAR and SNPnexus programs. The beta and se values of the single nucleotide polymorphisms validated in the discovery and validation studies were integrated through a meta-analysis based on a fixed-effects model.
[0072] 2) Fine-mapping
[0073] Fine-mapping was performed to identify potential causal variants among single nucleotide polymorphisms in the GWAS using the Sum of Single Effects (SuSiE) method. Regions were selected within + / - 100 kb around the read SNPs estimated to be the strongest association signals. Based on repetitive Bayesian stepwise selection (IBSS), the effects of LD structures were isolated to calculate the Posterior Inclusion Probability (PIP), which is the probability that a single nucleotide polymorphism is included in the causal relationship. A reliable set was generated through repetitive model fitting, which is created by ranking single nucleotide polymorphisms from the largest PIP to the smallest PIP. Fine-mapping was performed using the "susieR" R package.
[0074] D) Result
[0075] 1) Single nucleotide polymorphisms significantly associated with increased hsCRP gradient in high-risk hsCRP groups
[0076] In the whole-genome association analysis conducted based on the Korean Chip Consortium, a total of 82 significantly derived single nucleotide polymorphisms with a discovery analysis criterion P-value of less than 1e-07 were identified in the discovery and validation analyses, and the Manhattan plot and QQ plot for the discovery analysis results are shown (see Fig. 2).
[0077] 2) Cross-phenomenal Search
[0078] Based on previous studies, the HELZ gene was identified as having a crossover phenotype in genome-wide association analysis for chronic inflammation markers such as lymphocyte count, lymphocyte percentage in leukocytes, and neutrophil percentage in leukocytes (see Fig. 4).
[0079] 2) Fine-mapping results
[0080] As a result of zooming in on the regional plot and performing fine-mapping at 100 kb intervals, rs143984685 in the 17:65130819-65330819 region of the 17q24.2 cytoband based on PIP was derived as a credible set that can be considered as a potentially causal single nucleotide polymorphism (see Figs. 3 and 5).
[0081] Meanwhile, the global biomarker market is projected to grow from $27.95 billion in 2016 at an average annual growth rate of 13.8% to reach $53.34 billion in 2021. In particular, bioinformatics is projected to grow from $3.784 billion in 2015 at an average annual growth rate of 9.7% to reach $6.013 billion in 2020. With the current advancement of various biomarker analysis technologies, the biomarker industry for personalized medicine based on these technologies is expected to achieve continuous growth.
[0082] Therefore, by using the biomarkers identified by the present invention to prevent chronic inflammatory diseases in advance and by proposing systematic treatment and management methods for people exposed to major risk factors, it is possible to contribute to reducing the socioeconomic costs of chronic inflammation-related diseases.
[0083] The biomarkers based on the Korean chip database developed by this invention are expected to elevate the status of the medical industry and emerge as a high-profit business by realizing personalized medicine. Furthermore, since this invention is a technology based on genomic analysis that holds great potential for application in various chronic diseases in the future, it is expected that technological advancements in the diagnostic field will foster specialized research personnel and contribute to solving the problem of youth unemployment in science and engineering.
[0084] Furthermore, according to the present invention, repeated and continuous monitoring of hsCRP in high-risk hsCRP groups can be performed to proactively intervene in chronic inflammation-related diseases from a natural history perspective. In fact, while CRP has primarily been used as a follow-up test for inflammation or infection as an acute-phase reactant, hsCRP, which allows for low-concentration measurement, is utilized as a risk predictor for coronary artery disease. By revealing that the discovered biomarker is a pleiotropic expression that can be associated with various cross-phenotypes, the present invention comprehensively considers biological mechanisms commonly associated with various diseases to identify key biomarkers capable of intervening in chronic inflammatory diseases, thereby proposing targets for preventive intervention. This suggests that if new clinical indications based on this are identified, various biomarkers can be used for purposes other than their existing objectives.
[0085] Furthermore, this invention can serve as an opportunity to overcome the limitations of existing epidemiological modeling and maximize overall data analysis capabilities by utilizing genomic analysis technology. By screening high-risk groups for hsCRP and continuously monitoring hsCRP, it can provide an opportunity to gain domestic and international recognition for the level of diagnostic and preventive technologies for chronic inflammatory diseases, and is expected to serve as an important foundational technology closely related to the pharmaceutical and healthcare industries. It is anticipated that this will enable the reduction of the socioeconomic burden of chronic inflammatory diseases, which are increasing annually, and the realization of personalized medicine by identifying biological mechanisms and causes based on techniques for identifying pleiotropic biomarkers associated with cross-phenotypes.
[0086] Furthermore, the present invention may provide evidence for targeting hsCRP as a marker for the prevention and treatment of systemic inflammation. Continuous monitoring of hsCRP may capture information regarding chronic inflammation better than studies based on a single baseline. Changes in hsCRP or sustained elevations of hsCRP have the potential to add clinical value compared to a single measurement, and through cross-phenotypic association verification, it can be regarded as a biomarker applicable inclusively to chronic inflammatory diseases rather than hsCRP-specific genetic variants; this is expected to improve reliability based on a comprehensive biological understanding and lead to stronger associations with outcomes. Regardless of whether hsCRP is involved in a causal pathway or is simply a marker of the pathogenesis of these outcomes, the increasing trend of hsCRP in high-risk groups following multiple measurements of hsCRP derived in the present invention suggests that it may better indicate the risk of chronic inflammation.
[0087] The relevant biomarkers identified in the present invention can potentially provide information for identifying high-risk participants for risk classification and randomized clinical trials, and can provide insights into the etiology of related diseases and potential therapeutic targets through continuous monitoring of hsCRP in a healthy population.
[0088] In particular, the present invention can provide a composition for predicting the occurrence of neurological diseases related to systemic inflammation in Koreans, comprising a preparation capable of detecting a single nucleotide polymorphism of rs143984685 (NCBI refSNP ID), and a kit comprising the same. The present invention can provide information for predicting chronic inflammation-related diseases by identifying cross-phenotypes associated with the occurrence of chronic and systemic inflammation-related diseases in the hsCRP high-risk group of the general population, and at the same time, can provide pleiotropic information regarding the biological mechanism possessed by the said single nucleotide polymorphism.
[0089] Accordingly, the present invention provides a kit capable of predicting diseases related to chronic inflammation in a high-risk sCRP group, wherein the kit is an RT-PCR kit, a microarray chip, or a microfluidic chip. Detection of single nucleotide polymorphisms can be performed by sequencing, mini-sequencing, automated sequencing, TaqMan analysis, pyrosequencing, allele-specific PCR, dynamic allele-specific hybridization (DASH), PCR-RFLP (restriction fragment length polymorphism), PCR-SSCP (single strand conformation polymorphism), PCR-SSO (specific sequence oligonucleotide), hybridization by microarray, primer extension, Southern blot hybridization, dot hybridization, ASO (allele-specific oligonucleotide) hybridization combining PCR-SSO and dot hybridization, RCA (rolling circle amplification), HRM (high resolution melting), or MALDI-TOF / MS (matrix-assisted laser desorption ionization-time of flight mass spectrometry).
[0090] Below, based on the details described above, we will briefly examine the operation flow of the present invention.
[0091] FIG. 6 is a flowchart of the operation of a method for analyzing chronic inflammatory diseases based on whole-genome association analysis according to one embodiment of the present invention.
[0092] The method for analyzing chronic inflammatory diseases based on whole-genome association shown in FIG. 6 can be performed by the analysis device (100) described above. Therefore, even if the details are omitted below, the description of the analysis device (100) can be applied equally to the description of FIG. 6.
[0093] Referring to FIG. 6, in step S11, the diagnostic information generation unit (130) can collect the subject's hsCRP (high-sensitivity C-reactive protein) levels during the follow-up period.
[0094] Next, in step S12, the diagnostic information generation unit (130) can generate diagnostic information associated with the degree of inflammation of the subject based on at least one of the hsCRP level and the time series change of the hsCRP level.
[0095] In the description above, steps S11 and S12 may be further subdivided into additional steps or combined into fewer steps, depending on the embodiment of the present invention. Additionally, some steps may be omitted as necessary, and the order between steps may be changed.
[0096] A method for analyzing chronic inflammatory diseases based on whole-genome association analysis according to one embodiment of the present invention may be implemented in the form of program instructions that can be executed through various computer means and recorded on a computer-readable medium. The computer-readable medium may include program instructions, data files, data structures, etc., either individually or in combination. The program instructions recorded on the medium may be those specifically designed and configured for the present invention, or they may be those known and available to those skilled in the art of computer software. Examples of computer-readable recording media include magnetic media such as hard disks, floppy disks, and magnetic tapes; optical recording media such as CD-ROMs and DVDs; magneto-optical media such as floptical disks; and hardware devices specifically configured to store and execute program instructions, such as ROM, RAM, and flash memory. Examples of program instructions include machine code, such as that generated by a compiler, as well as high-level language code that can be executed by a computer using an interpreter, etc. The above-described hardware device may be configured to operate as one or more software modules to perform the operation of the present invention, and vice versa.
[0097] In addition, the aforementioned method for analyzing chronic inflammatory diseases based on whole-genome association analysis can also be implemented in the form of a computer program or application executed by a computer and stored on a recording medium.
[0098] The foregoing description of the present invention is for illustrative purposes only, and those skilled in the art will understand that other specific forms can be easily modified without altering the technical concept or essential features of the present invention. Therefore, the embodiments described above should be understood as illustrative in all respects and not restrictive. For example, each component described as a single unit may be implemented in a distributed manner, and components described as distributed may likewise be implemented in a combined form.
[0099] The scope of the present invention is defined by the claims set forth below rather than by the detailed description above, and all modifications or variations derived from the meaning and scope of the claims and the concept of equivalents thereof should be interpreted as being included within the scope of the present invention. Explanation of the symbols
[0100] 100: Genome-based association analysis device for chronic inflammatory diseases 110: Collection Department 120: Statistical Analysis Department 130: Diagnostic Information Generation Unit
Claims
Claim 1 A method for analyzing chronic inflammatory diseases based on whole-genome association analysis, performed by a device for analyzing chronic inflammatory diseases based on whole-genome association analysis, comprising: a step of collecting genomic information data of a plurality of subjects; a step of selecting genomic information data that satisfies a preset hsCRP level condition based on hsCRP (high-sensitivity C-reactive protein) level information of each of the plurality of subjects; a step of performing whole-genome association analysis based on a linear regression model linked to an hsCRP gradient using the selected genomic information data; and a step of deriving analysis information on a single nucleotide polymorphism that is significantly associated with a phenotype linked to a target disease based on the results of the association analysis, wherein the target disease includes a chronic inflammatory disease and the single nucleotide polymorphism includes rs143984685. Claim 2 delete Claim 3 The analysis method according to claim 1, wherein the selection step is to select the genomic information data of a subject among the plurality of subjects in which the hsCRP level corresponds to a preset threshold value or higher during the follow-up observation time and the change in the hsCRP level corresponds to a preset threshold slope or higher. Claim 4 The analysis method according to claim 1, wherein the step of deriving the analysis information is to determine a single nucleotide polymorphism among the single nucleotide polymorphisms derived by the association analysis that corresponds to a P-value less than a preset threshold and can be considered to have significant genomic association. Claim 5 delete Claim 6 An analysis method according to claim 1, further comprising the step of generating diagnostic information regarding the target disease of the subject using the analysis information. Claim 7 An analysis device for chronic inflammatory diseases based on whole-genome association analysis, comprising: a collection unit that collects genomic information data of multiple subjects and selects genomic information data satisfying a preset hsCRP level condition based on hsCRP (high-sensitivity C-reactive protein) level information of each of the multiple subjects; and a statistical analysis unit that performs whole-genome association analysis based on a linear regression model linked to an hsCRP gradient using the selected genomic information data and derives analysis information regarding a single nucleotide polymorphism significantly associated with a phenotype linked to a target disease based on the results of the association analysis, wherein the target disease includes a chronic inflammatory disease and the single nucleotide polymorphism includes rs143984685. Claim 8 An analysis device according to claim 7, further comprising a diagnostic information generation unit that generates diagnostic information regarding the target disease of a subject using the analysis information. Claim 9 A composition for detecting a single nucleotide polymorphism (SNP) marker to predict the occurrence and exacerbation of chronic inflammatory diseases, wherein the single nucleotide polymorphism (SNP) marker is rs143984685. Claim 10 A kit for diagnosing the prediction of onset and exacerbation of chronic inflammatory diseases using a single nucleotide polymorphism (SNP) marker, wherein the single nucleotide polymorphism (SNP) marker is rs143984685.
Citation Information
Patent Citations
Marker for predicting exacerbation of chronic kidney disease and method for predicting exacerbation using the same
KR102189144B1
